Fludeoxyglucose f-18
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Radioactive Diagnostic Agent
Dosing in kidney impairment
| Organ | Newborn (3.4kg) | 1-year old (9.8kg) | 5-year old (19kg) | 10-year old (32kg) | 15-year old (57kg) | Adult (70kg) |
| Bladder wallb | 4.3 | 1.7 | 0.93 | 0.60 | 0.40 | 0.32 |
| Heart wall | 2.4 | 1.2 | 0.70 | 0.44 | 0.29 | 0.22 |
| Pancreas | 2.2 | 0.68 | 0.33 | 0.25 | 0.13 | 0.096 |
| Spleen | 2.2 | 0.84 | 0.46 | 0.29 | 0.19 | 0.14 |
| Lungs | 0.96 | 0.38 | 0.20 | 0.13 | 0.092 | 0.064 |
| Kidneys | 0.81 | 0.34 | 0.19 | 0.13 | 0.089 | 0.074 |
| Ovaries | 0.80 | 0.8 | 0.19 | 0.11 | 0.058 | 0.053 |
| Uterus | 0.79 | 0.35 | 0.19 | 0.12 | 0.076 | 0.062 |
| LLI wall* | 0.69 | 0.28 | 0.15 | 0.097 | 0.060 | 0.051 |
| Liver | 0.69 | 0.31 | 0.17 | 0.11 | 0.076 | 0.058 |
| Gallbladder wall | 0.69 | 0.26 | 0.14 | 0.093 | 0.059 | 0.049 |
| Small intestine | 0.68 | 0.29 | 0.15 | 0.096 | 0.060 | 0.047 |
| ULI wall** | 0.67 | 0.27 | 0.15 | 0.090 | 0.057 | 0.046 |
| Stomach wall | 0.65 | 0.27 | 0.14 | 0.089 | 0.057 | 0.047 |
| Adrenals | 0.65 | 0.28 | 0.15 | 0.095 | 0.061 | 0.048 |
| Testes | 0.64 | 0.27 | 0.14 | 0.085 | 0.052 | 0.041 |
| Red marrow | 0.62 | 0.26 | 0.14 | 0.089 | 0.057 | 0.047 |
| Thymus | 0.61 | 0.26 | 0.14 | 0.086 | 0.056 | 0.044 |
| Thyroid | 0.61 | 0.26 | 0.13 | 0.080 | 0.049 | 0.039 |
| Muscle | 0.58 | 0.25 | 0.13 | 0.078 | 0.049 | 0.039 |
| Bone surface | 0.57 | 0.24 | 0.12 | 0.079 | 0.052 | 0.041 |
| Breast | 0.54 | 0.22 | 0.11 | 0.068 | 0.043 | 0.034 |
| Skin | 0.49 | 0.20 | 0.10 | 0.060 | 0.037 | 0.030 |
| Brain | 0.29 | 0.13 | 0.09 | 0.078 | 0.072 | 0.070 |
| Other tissues | 0.59 | 0.25 | 0.13 | 0.083 | 0.052 | 0.042 |
| Organ | Newborn (3.4kg) | 1-year old (9.8kg) | 5-year old (19kg) | 10-year old (32kg) | 15-year old (57kg) | Adult (70kg) |
| Bladder wallb | 4.3 | 1.7 | 0.93 | 0.60 | 0.40 | 0.32 |
| Heart wall | 2.4 | 1.2 | 0.70 | 0.44 | 0.29 | 0.22 |
| Pancreas | 2.2 | 0.68 | 0.33 | 0.25 | 0.13 | 0.096 |
| Spleen | 2.2 | 0.84 | 0.46 | 0.29 | 0.19 | 0.14 |
| Lungs | 0.96 | 0.38 | 0.20 | 0.13 | 0.092 | 0.064 |
| Kidneys | 0.81 | 0.34 | 0.19 | 0.13 | 0.089 | 0.074 |
| Ovaries | 0.80 | 0.8 | 0.19 | 0.11 | 0.058 | 0.053 |
| Uterus | 0.79 | 0.35 | 0.19 | 0.12 | 0.076 | 0.062 |
| LLI wall* | 0.69 | 0.28 | 0.15 | 0.097 | 0.060 | 0.051 |
| Liver | 0.69 | 0.31 | 0.17 | 0.11 | 0.076 | 0.058 |
| Gallbladder wall | 0.69 | 0.26 | 0.14 | 0.093 | 0.059 | 0.049 |
| Small intestine | 0.68 | 0.29 | 0.15 | 0.096 | 0.060 | 0.047 |
| ULI wall** | 0.67 | 0.27 | 0.15 | 0.090 | 0.057 | 0.046 |
| Stomach wall | 0.65 | 0.27 | 0.14 | 0.089 | 0.057 | 0.047 |
| Adrenals | 0.65 | 0.28 | 0.15 | 0.095 | 0.061 | 0.048 |
| Testes | 0.64 | 0.27 | 0.14 | 0.085 | 0.052 | 0.041 |
| Red marrow | 0.62 | 0.26 | 0.14 | 0.089 | 0.057 | 0.047 |
| Thymus | 0.61 | 0.26 | 0.14 | 0.086 | 0.056 | 0.044 |
| Thyroid | 0.61 | 0.26 | 0.13 | 0.080 | 0.049 | 0.039 |
| Muscle | 0.58 | 0.25 | 0.13 | 0.078 | 0.049 | 0.039 |
| Bone surface | 0.57 | 0.24 | 0.12 | 0.079 | 0.052 | 0.041 |
| Breast | 0.54 | 0.22 | 0.11 | 0.068 | 0.043 | 0.034 |
| Skin | 0.49 | 0.20 | 0.10 | 0.060 | 0.037 | 0.030 |
| Brain | 0.29 | 0.13 | 0.09 | 0.078 | 0.072 | 0.070 |
| Other tissues | 0.59 | 0.25 | 0.13 | 0.083 | 0.052 | 0.042 |
Preparation and administration
Prepare this dose
Your numbers for fludeoxyglucose f-18. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Patient Preparation To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study. Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour.
Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [ see Warnings and Precautions ]. Prior to Fludeoxyglucose F 18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 – 6 hours prior to the drug’s injection. In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to Fludeoxyglucose F 18 Injection facilitates localization of cardiac ischemia.
Drug Preparation and Administration Calculate the necessary volume to administer based on calibration time and dose. Aseptically withdraw Fludeoxyglucose F 18 Injection from its container. Inspect Fludeoxyglucose F 18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit.
Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. Use Fludeoxyglucose F 18 Injection within 12 hours from the EOS.
Imaging Guidelines Initiate imaging within 40 minutes following Fludeoxyglucose F 18 Injection administration. Acquire static emission images 30 – 100 minutes from the time of injection.
Patient Preparation To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study. Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour.
Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [ see Warnings and Precautions ]. Prior to Fludeoxyglucose F 18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 – 6 hours prior to the drug’s injection. In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to Fludeoxyglucose F 18 Injection facilitates localization of cardiac ischemia.
Drug Preparation and Administration Calculate the necessary volume to administer based on calibration time and dose. Aseptically withdraw Fludeoxyglucose F 18 Injection from its container. Inspect Fludeoxyglucose F 18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit.
Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. Use Fludeoxyglucose F 18 Injection within 12 hours from the EOS.
Drug interactions
Check fludeoxyglucose f-18 against a medication listLabel text (1 paragraph)
The interaction of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.
Contraindications
None None
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for fludeoxyglucose f-18. Check the label's hepatic warnings.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.